Hims & Hers Stock Drops 12.8% After Short Report
Hims & Hers Stock Drops 12.8% After Short Report
Shares of online pharmacy Hims & Hers (NYSE: HIMS) dropped as much as 12.8% on Thursday after a short-seller wrote a report about the company. Shares recovered slightly during trading and are down 7.8% at 2:30 p.m. ET today.
The short-seller's report
Hunterbrook Media put out what appears to be a journalistic article, but it's in fact tied to Hunterbrook Capital, which is short the stock. As with any short report, investors should read it with an open mind but remain skeptical of the motivations of the writers.
In this case, Hunterbrook criticized Hims & Hers' GLP-1 weight-loss treatment, which is a compound made by a pharmacy and temporarily approved to fill shortages of GLP-1 drugs, and not a government-approved medication itself. There are questions, even by the Food and Drug Administration, about how effective the treatment is compared to approved versions of GLP-1.
The Hunterbrook report also criticized the company's prescription process and insider sales of the stock.
Risks at Hims & Hers
It isn't that the short-seller's report is incorrect, it's that it was presented in a way that only told one side of the story. Hims & Hers could be more rigorous in its prescription process and could improve the suppliers it uses. However, these same criticisms could be leveled at the traditional medical system.
As with any short report, I'm inclined to take this information as a solid bear case against the stock and monitor developments. But I also see this as a growing pain for a disruptive healthcare company that could be a net positive for investors and society.
Should you invest $1,000 in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $774,526!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
See the 10 stocks »
*Stock Advisor returns as of June 24, 2024
Travis Hoium has positions in Hims & Hers Health. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.